CD4+ T cells in atherosclerosis: Regulation by platelets

Thrombosis and Haemostasis

Volumn 109, Issue 6, 2013, Pages 980-990

  Li, Nailin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; CD4+ T cells; Chemokines; Cytokines; Platelets

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; FIBRINOGEN RECEPTOR; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; JUNCTIONAL ADHESION MOLECULE C; L SELECTIN; PADGEM PROTEIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SUPPRESSOR OF CYTOKINE SIGNALING 3; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANGIOGENESIS; ATHEROSCLEROSIS; AUTOCRINE EFFECT; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; EFFECTOR CELL; HEMOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LYMPHOCYTE SUBSETS; TH17 CELLS; TH2 CELLS; THROMBOSIS;

EID: 84878633967     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-11-0819     Document Type: Review

References (122)

1. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976; 295: 369-377.
2. Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 1999; 340: 115-126.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
4. Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998; 98: 2461-2469.
5. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
6. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
7. Schaffner T, Taylor K, Bartucci EJ, et al. Arterial foam cells with distinctive im-munomorphologic and histochemical features of macrophages. Am J Pathol 1980; 100: 57-80.
8. Jonasson L, Holm J, Skalli O, et al. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985; 76: 125-131.
9. Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macro-phages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-138.
10. Hansson GK. Immune Mechanisms in Atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
11. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
12. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from patho-physiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
13. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
14. Zhou X, Nicoletti A, Elhage R, et al. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000; 102: 2919-2922.
15. Zhou X, Robertson AK, Rudling M, et al. Lesion development and response to immunisation reveal a complex role for CD4 in atherosclerosis. Circ Res 2005; 96: 427-434.
16. Gao Q, Jiang Y, Ma T, et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 2010; 185: 5820-5827.
17. Tellides G, Tereb DA, Kirkiles-Smith NC, et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000; 403: 207-211.
18. Laurat E, Poirier B, Tupin E, et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001; 104: 197-202.
19. Buono C, Binder CJ, Stavrakis G, et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci USA 2005; 102: 1596-1601.
20. Gupta S, Pablo AM, Jiang X, et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-2761.
21. Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol 2008; 172: 1500-1508.
22. Binder CJ, Hartvigsen K, Chang MK, et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114: 427-437.
23. King VL, Cassis LA, Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol 2007; 171: 2040-2047.
24. King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/-mice. Arterioscler Thromb Vasc Biol 2002; 22: 456-461.
25. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-1125.
26. Bettelli E, Korn T, Oukka M, et al. Induction and effector functions of T(H)17 cells. Nature 2008; 453: 1051-1057.
27. Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008; 127: 89-97.
28. van Es T, van Puijvelde GH, Ramos OH, et al. Attenuated atherosclerosis upon IL-17R signalling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009; 388: 261-265.
29. Smith E, Stark MA, Zarbock A, et al. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through short-loop inhibition via IL-17 receptor. J Immunol 2008; 181: 1357-1364.
30. Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009; 206: 2067-2077.
31. de Boer OJ, van der Meer JJ, Teeling P, et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007; 2: e779.
32. Heller EA, Liu E, Tager AM, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006; 113: 2301-2312.
33. Mor A, Luboshits G, Planer D, et al. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006; 27: 2530-2537.
34. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180.
35. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
36. Pinderski LJ, Fischbein M P, Subbanagounder G, et al. Overexpression of inter-leukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-1071.
37. Mallat Z, Gojova A, Marchiol-Fournigault C, et al. Inhibition of transforming growth factor-beta signalling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001; 89: 930-934.
38. Robertson AK, Rudling M, Zhou X, et al. Disruption of TGF-beta signalling in T cells accelerates atherosclerosis. J Clin Invest 2003; 112: 1342-1350.
39. Sasaki N, Yamashita T, Takeda M, et al. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 2009; 120: 1996-2005.
40. Duguid JB. Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J Pathol Bacteriol 1948; 60: 57-61.
41. Theilmeier G, Michiels C, Spaepen E, et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis- prone sites in response to hypercholeste-rolemia. Blood 2002; 99: 4486-4493.
42. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
43. Theilmeier G, Lenaerts T, Remacle C, et al. Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. Blood 1999; 94: 2725-2734.
44. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000; 101: 2290-2295.
45. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005; 25: 1321-1324.
46. Hu H, Zhu L, Huang Z, et al. Platelets enhance lymphocyte adhesion and infiltration into arterial thrombus. Thromb Haemost 2010; 104: 1184-1192.
47. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67.
48. Massberg S, Schurzinger K, Lorenz M, et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischaemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 2005; 112: 1180-1188.
49. Dong ZM, Chapman SM, Brown AA, et al. The combined role of P- and E-selec-tins in atherosclerosis. J Clin Invest 1998; 102: 145-152.
50. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
51. Koenen RR, Weber C. Platelet-derived chemokines in vascular remodeling and atherosclerosis. Semin Thromb Hemost 2010; 36: 163-169.
52. Koyama H, Maeno T, Fukumoto S, et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 2003; 108: 524-529.
53. Stellos K, Bigalke B, Stakos D, et al. Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myo-cardial necrosis, and effect of diabetes mellitus and anti-platelet medication. J Thromb Haemost 2010; 8: 205-207.
54. Fateh-Moghadam S, Li Z, Ersel S, et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol 2005; 25: 1299-1303.
55. Kuijper PH, Gallardo TH, Lammers J W, et al. Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood 1997; 89: 166-175.
56. Kuijper PHM, Gallardo Torres HI, van der Linden JAM, et al. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood 1996; 87: 3271-3281.
57. Kuijper PH, Gallardo TH, Houben LA, et al. P-selectin and MAC-1 mediate monocyte rolling and adhesion to ECM-bound platelets under flow conditions. J Leukocyte Biol 1998; 64: 467-473.
58. Lalor P, Nash GB. Adhesion of flowing leucocytes to immobilized platelets. Br J Haematol 1995; 89: 725-732.
59. Kirton CM, Nash GB. Activated platelets adherent to an intact endothelial cell monolayer bind flowing neutrophils and enable them to transfer to the endothe-lial surface. J Lab Clin Med 2000; 136: 303-313.
60. Butler LM, Metson-Scott T, Felix J, et al. Sequential adhesion of platelets and leukocytes from flowing whole blood onto a collagen-coated surface: requirement for a GpVI-binding site in collagen. Thromb Haemost 2007; 97: 814-821.
61. Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997; 89: 1270-1278.
62. Diacovo TG, Puri KD, Warnock RA, et al. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996; 273: 252-255.
63. Diacovo TG, Catalina MD, Siegelman MH, et al. Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice. J Exp Med 1998; 187: 197-204.
64. Solpov A, Shenkman B, Vitkovsky Y, et al. Platelets enhance CD4+ lymphocyte adhesion to extracellular matrix under flow conditions: role of platelet aggregation, integrins, and non-integrin receptors. Thromb Haemost 2006; 95: 815-821.
65. Schulz C, Schafer A, Stolla M, et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764-773.
66. Spectre G, Zhu L, Ersoy M, et al. Platelets selectively enhance lymphocyte adhesion on subendothelial matrix under arterial flow conditions. Thromb Hae-most 2012; 108: 328-337.
67. Eriksson EE. Intravital microscopy on atherosclerosis in apolipoprotein e-defi-cient mice establishes microvessels as major entry pathways for leukocytes to advanced lesions. Circulation 2011; 124: 2129-2138.
68. Yoshizaki A, Yanaba K, Iwata Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-2515.
69. Taub DD, Turcovski-Corrales SM, Key ML, et al. Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol 1996; 156: 2095-2103.
70. Bacon KB, Premack BA, Gardner P, et al. Activation of dual T cell signalling pathways by the chemokine RANTES. Science 1995; 269: 1727-1730.
71. Acres RB, Lamb JR, Feldman M. Effects of platelet-derived growth factor and epidermal growth factor on antigen-induced proliferation of human T-cell lines. Immunology 1985; 54: 9-16.
72. Kabashima K, Murata T, Tanaka H, et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol 2003; 4: 694-701.
73. Thomas DW, Rocha PN, Nataraj C, et al. Proinflammatory actions of thrombox-ane receptors to enhance cellular immune responses. J Immunol 2003; 171: 6389-6395.
74. Vivier E, Deryckx S, Wang JL, et al. Immunoregulatory functions of paf-acether. VI. Inhibition of T cell activation via CD3 and potentiation of T cell activation via CD2. Int Immunol 1990; 2: 545-553.
75. Ayoub IA, Yang TJ. Growth regulatory effects of transforming growth factor-beta 1 and interleukin-2 on IL-2 dependent CD4+T lymphoblastoid cell line. Immunol Invest 1996; 25: 129-151.
76. Fleischer J, Grage-Griebenow E, Kasper B, et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 2002; 169: 770-777.
77. Liu CY, Battaglia M, Lee SH, et al. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells. J Immunol 2005; 174: 2680-2686.
78. Gerdes N, Zhu L, Ersay M, et al. Platelets regulate CD4+ T cell differentiation via multiple chemokines in humans. Thromb Haemost 2011; 106: 353-362.
79. Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-982.
80. Gojova A, Brun V, Esposito B, et al. Specific abrogation of transforming growth factor-beta signalling in T cells alters atherosclerotic lesion size and composition in mice. Blood 2003; 102: 4052-4058.
81. Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453: 236-240.
82. Lievens D, Habets KL, Robertson AK, et al. Abrogated transforming growth factor beta receptor II (TGFbetaRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur Heart J 2012; epub ahead of print.
83. Calabresse C, Nguer MC, Pellegrini O, et al. Induction of high-affinity paf receptor expression during T cell activation. Eur J Immunol 1992; 22: 1349-1355.
84. Frostegard J, Huang YH, Ronnelid J, et al. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997; 17: 963-968.
85. Prescott SM, Zimmerman GA, Stafforini DM, et al. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000; 69: 419-445.
86. Masini E, Di Bello MG, Raspanti S, et al. The role of histamine in platelet aggregation by physiological and immunological stimuli. Inflamm Res 1998; 47: 211-220.
87. Jutel M, Klunker S, Akdis M, et al. Histamine upregulates Th1 and downregu-lates Th2 responses due to different patterns of surface histamine 1 and 2 receptor expression. International archives of allergy and immunology 2001; 124: 190-192.
88. Li N, Wallén NH, Ladjevardi M, et al. Effects of serotonin on platelet activation in whole blood. Blood Coagulation And Fibrinolysis 1997; 8: 517-523.
89. Ameisen JC, Meade R, Askenase PW. A new interpretation of the involvement of serotonin in delayed-type hypersensitivity. Serotonin-2 receptor antagonists inhibit contact sensitivity by an effect on T cells. J Immunol 1989; 142: 3171-3179.
90. Inoue M, Okazaki T, Kitazono T, et al. Regulation of antigen-specific CTL and Th1 cell activation through 5-Hydroxytryptamine 2A receptor. Int Immunoph-armacol 2011; 11: 67-73.
91. Geba GP, Ptak W, Anderson GM, et al. Delayed-type hypersensitivity in mast cell-deficient mice: dependence on platelets for expression of contact sensitivity. J Immunol 1996; 157: 557-565.
92. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signalling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-490.
93. Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immu-nopathol 2012; 34: 5-30.
94. Hebel K, Rudolph M, Kosak B, et al. IL-1beta and TGF-beta act antagonistically in induction and differentially in propagation of human proinflammatory precursor CD4+ T cells. J Immunol 2011; 187: 5627-5635.
95. Acosta-Rodriguez E V, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-949.
96. Shaw MH, Kamada N, Kim YG, et al. Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med 2012; 209: 251-258.
97. Drolet AM, Thivierge M, Turcotte S, et al. Platelet-activating factor induces Th17 cell differentiation. Mediators Inflamm 2011; 2011: 913802.
98. Singh T P, Huettner B, Koefeler H, et al. Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-beta1 transgenic mice. Am J Pathol 2011; 178: 699-708.
99. Huang YH, Schafer-Elinder L, Owman H, et al. Induction of IL-4 by platelet-activating factor. Clin Exp Immunol 1996; 106: 143-148.
100. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol 2005; 238: 1-9.
101. Elzey BD, Grant JF, Sinn H W, et al. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukoc Biol 2005; 78: 80-84.
102. Elzey BD, Tian J, Jensen RJ, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9-19.
103. Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52: 1435-1441.
104. Hansson GK. The B cell: a good guy in vascular disease? Arterioscler Thromb Vasc Biol 2002; 22: 523-524.
105. Mallat Z, Gojova A, Brun V, et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knock-out mice. Circulation 2003; 108: 1232-1237.
106. Ganesh BB, Bhattacharya P, Gopisetty A, et al. IL-1beta promotes TGF-beta1 and IL-2 dependent Foxp3 expression in regulatory T cells. PLoS One 2011; 6: e21949.
107. Maganto-Garcia E, Tarrio ML, Grabie N, et al. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation 2011; 124: 185-195.
108. Caligiuri G, Nicoletti A. Tregs and human atherothrombotic diseases: toward a clinical application? Arterioscler Thromb Vasc Biol 2010; 30: 1679-1681.
109. Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
110. Andersson PO, Stockelberg D, Jacobsson S, et al. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000; 79: 507-513.
111. Alcaide P, Maganto-Garcia E, Newton G, et al. Difference in Th1 and Th17 lymphocyte adhesion to endothelium. J Immunol 2012; 188: 1421-1430.
112. Konstantopoulos K, Neelamegham S, Burns AR, et al. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation 1998; 98: 873-882.
113. Larsen E, Palabrica T, Sajer S, et al. PADGEM-dependent adhesion of platelets to monocytes and neutrophils is mediated by a lineage-specific carbohydrate, LNF III (CD15). Cell 1990; 63: 467-474.
114. Spangenberg P, Redlich H, Bergmann I, et al. The platelet glycoprotein IIb/IIIa complex is involved in the adhesion of activated platelets to leukocytes. Thromb Haemost 1993; 70: 514-521.
115. André P, Prasad KS, Denis C V, et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002; 8: 247-252.
116. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterrecep-tor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
117. Santoso S, Sachs UJ, Kroll H, et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002; 196: 679-691.
118. Li N, Ji Q, Hjemdahl P. Platelet-lymphocyte conjugation differs between lymphocyte subpopulations. J Thromb Haemost 2006; 4: 874-881.
119. Lichtman AH, Chin J, Schmidt JA, et al. Role of interleukin 1 in the activation of T lymphocytes. Proc Natl Acad Sci U S A 1988; 85: 9699-9703.
120. Miconnet I, Pantaleo G. A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. Vaccine 2008; 26: 4006-4014.
121. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413: 420-425.
122. Steffens S, Burger F, Pelli G, et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 2006; 114: 1977-1984.